Ideaya biosciences and hengrui pharma present positive phase 1 data for ide849 (shr-4849), a potential first-in-class dll3 top1 adc, in small cell lung cancer at the iaslc 2025 world conference on lung cancer

80.0% (8/10) orr and 70.0% (7/10) confirmed orr in 2l sclc; a 73.7% (14/19) orr and 57.9% (11/19) confirmed orr (1 pending confirmation) were observed across all lines of sclc at the 2.4 mg/kg expansion dose of ide849 77.1% (27/35) orr and 60.0% (21/35) confirmed orr (4 pending confirmation) in 2l sclc; a 73.2% (52/71) orr and 47.9% (34/71) confirmed orr (10 pending confirmation) were observed across all lines of sclc at all expansion doses of ide849 in patients with baseline brain metastases, a 83.3% (5/6) confirmed orr at the 2.4 mg/kg dose was observed; across all doses ≥2.4 mg/kg (n=18), a 66.7% (12/18) confirmed orr (1 pending confirmation) was observed 14.1% (10/71) of patients across all doses > 2.4 mg/kg are still pending confirmation, as well as multiple patients that have had limited follow-up (e.g. one post-baseline scan) highlighting the study has not yet achieved a fully mature confirmed orr% 6.7 month median progression free survival (pfs) across all lines of sclc across all dose levels (≥2.4 mg/kg); mpfs not reached in 2l sclc patients manageable safety profile observed across multiple expansion cohorts, including the 2.4 mg/kg, 3.0 mg/kg, and 3.5 mg/kg dose levels with a once every 3-week dosing interval shanghai and south san francisco, calif.
TOP Ratings Summary
TOP Quant Ranking